Response time with carfilzomib

Carfilzomib (Carfilzomib) can usually prolong the progression-free survival and overall survival of patients with multiple myeloma, but the specific response time varies from person to person and depends on factors such as the patient's condition, physical condition, treatment plan, and the dosage and usage of the drug. According to clinical trial data, the median response time of patients treated with carfilzomib is more than 3 years, and some patients can even achieve long-term response. Generally speaking, before using carfilzomib, doctors will conduct a comprehensive physical examination and evaluation, and formulate an appropriate treatment plan based on the patient's specific situation to prolong the patient's survival and improve the quality of life as much as possible.